BCL-2 Inhibitor Crystal Form for Selectivity and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing BCL-2 inhibitors lack selectivity for specific proteins and have stability and pharmacokinetic issues, affecting their druggability and suitability for therapeutic applications.
Innovation Solution
Development of crystalline forms of a trifluoromethyl/chloro disubstituted sulfonamide compound with specific X-ray powder diffraction patterns, characterized by distinct peaks, which enhance stability and pharmacokinetic properties, allowing for selective binding to BCL-2 and BCL-XL proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing BCL-2 inhibitors are used, then binding affinity to target protein is achieved, but selectivity for specific proteins is insufficient
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups (trifluoromethyl and chloro) at particular positions on the sulfonamide core structure. These localized chemical modifications create specific interaction patterns with BCL-2 and BCL-XL proteins, enhancing selectivity while maintaining binding affinity. The discrete structural changes at specific molecular locations enable differential binding to target proteins.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters including substituent types (fluoromethyl, chloro), their positions on the aromatic ring, and stereochemical configurations. These parameter modifications tune the binding characteristics of the inhibitor, optimizing both affinity and selectivity for BCL-2 over other BCL-2 family proteins through precise molecular property adjustment.
2Stability of the object's composition
If compound stability is improved, then pharmacokinetic properties are enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by establishing stable crystalline forms of the compound during the drug development process. The specific crystal structure (Form A with defined XRPD peaks) is prepared in advance, ensuring stability and consistent pharmacokinetic properties. This pre-established crystalline form facilitates subsequent manufacturing processes by providing a stable starting material with predictable behavior.
Solution Approach 2:
The patent employs composite materials by creating a specific crystalline structure that combines the sulfonamide core with particular substituent arrangements. The crystalline Form A represents a composite organizational state of the molecules, where intermolecular interactions create a stable lattice structure. This composite crystalline form enhances stability while the defined structure actually simplifies manufacturing by providing consistent physical properties for processing.
3Stability of the object's composition
If crystalline form stability is enhanced, then storage and formulation requirements are met, but characterization and detection difficulty increases
Solution Approach 1:
The patent applies the principle of physical property changes by establishing specific X-ray powder diffraction (XRPD) patterns as characteristic fingerprints for Crystal Form A. The defined diffraction peaks at specific 2θ angles serve as detectable signatures that enable identification and characterization of the crystalline form. This approach transforms the stability advantage into a measurable characteristic through diffraction pattern analysis.
Solution Approach 2:
The patent replaces complex stability assessment mechanisms with simplified detection methods. Instead of requiring complex stability testing, the defined XRPD pattern provides a rapid, non-destructive method to confirm crystal form identity and stability. The characteristic diffraction peaks serve as a substitute for extensive stability characterization, enabling quick verification through standard X-ray diffraction equipment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms exhibit improved stability, solubility, and pharmacokinetic properties, ensuring better drug performance and ease of preparation, meeting requirements for drug production and storage.
Implementation Method 1
which is characterized by having peaks at 2θ of 5.01, 6.61, 8.12 or 20.13±0.2° in an X-ray powder diffraction pattern
Data Source
AI summary
A crystal of a trifluoromethyl/chloro disubstituted sulfonamide selective BCL-2 inhibitor, specifically related to a crystal of a compound of formula I, a preparation method therefor, and use thereof in preventing and treating diseases related to anti-apoptotic protein BCL-2, such as cancers.